Back to Search Start Over

Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts

Authors :
A. Yu. Lebedeva
O. M. Koteshkova
O. N. Dzhioeva
S. R. Gilyarevsky
T. M. Uskach
M. S. Novikova
Ya. A. Orlova
V. Yu. Kalashnikov
D. V. Privalov
N. A. Ananicheva
M. Yu. Gilyarov
A. D. Erlikh
Source :
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 1, Pp 165-168 (2021)
Publication Year :
2021
Publisher :
Столичная издательская компания, 2021.

Abstract

The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.

Details

Language :
English, Russian
ISSN :
18196446 and 22253653
Volume :
17
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Рациональная фармакотерапия в кардиологии
Publication Type :
Academic Journal
Accession number :
edsdoj.8642d167fac5420cbea6c65fee3a0b3e
Document Type :
article
Full Text :
https://doi.org/10.20996/1819-6446-2021-01-03